News
-
-
PRESS RELEASE
FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals plans single-blind extension phase for crofelemer trial in pediatric MVID patients, aiming to reduce parenteral support and improve clinical benefit. FDA supports protocol amendment -
-
PRESS RELEASE
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression
Magdalena Biosciences initiates preclinical study on whole leaf coca extract for appetite suppression post-GLP-1 weight loss. Study conducted in Alberta, Canada -
-
PRESS RELEASE
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. to present virtually at Life Sciences Investor Forum on March 12, 2026. More about Jaguar's novel prescription drugs for gastrointestinal diseases -
-
PRESS RELEASE
Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants
Jaguar Health, Inc. strengthens balance sheet by restructuring debt and royalty obligations. Sharp focus on global development program for crofelemer. CEO Lisa Conte prioritizes capitalization -
-
